Fig. 3.
Cumulative use of systemic therapies during the first three years since the diagnosis of HR+/HER2− advanced breast cancer with 95% confidence intervals, per period of diagnosis. See Supplementary Fig. S1 for the graphs of the cumulative use of these systemic agents.